Browse by People

Collapse authors list.
Munir, Talha, Cairns, David A, Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew ORCID: 0000-0002-0907-8950, Paneesha, Shankara, Fox, Christopher P, Eyre, Toby A, Forconi, Francesco ORCID: 0000-0002-2211-1831 et al (show 23 more authors) , Elmusharaf, Nagah, Kennedy, Ben, Gribben, John, Pemberton, Nicholas, Sheehy, Oonagh, Preston, Gavin, Schuh, Anna, Walewska, Renata, Duley, Lelia ORCID: 0000-0001-6721-5178, Howard, Dena, Hockaday, Anna, Jackson, Sharon, Greatorex, Natasha, Girvan, Sean, Bell, Sue, Brown, Julia M, Webster, Nichola, Dalal, Surita, de Tute, Ruth, Rawstron, Andrew, Patten, Piers EM ORCID: 0000-0003-3320-3034, Hillmen, Peter and National Cancer Research Institute Chronic Lymphocytic Leukemia , (2024) Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. The New England journal of medicine, 390 (4). pp. 326-337.

Collapse authors list.
Fox, Christopher P ORCID: 0000-0002-6322-9254, Chaganti, Sridhar, McIlroy, Graham ORCID: 0000-0002-4731-1784, Barrington, Sally F, Burton, Cathy, Cwynarski, Kate ORCID: 0000-0001-9936-3431, Eyre, Toby A ORCID: 0000-0002-6631-9749, Illidge, Timothy, Kalakonda, Nagesh ORCID: 0000-0002-5300-1360, Kuhnl, Andrea ORCID: 0000-0002-4952-2550 et al (show 2 more authors) , McKay, Pam ORCID: 0000-0002-3959-9730 and Davies, Andrew J (2024) The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. British journal of haematology, 204 (4). pp. 1178-1192.

Collapse authors list.
Eyre, Toby A, Hildyard, Catherine, Hamblin, Angela, Ali, Ayesha S, Houlton, Aimee, Hopkins, Louise, Royston, Daniel, Linton, Kim M, Pettitt, Andrew, Rule, Simon et al (show 11 more authors) , Cwynarski, Kate, Barrington, Sally F, Warbey, Victoria, Wrench, David, Barrans, Sharon, Hirst, Caroline S, Panchal, Anesh, Roudier, Martine P, Harrington, Elizabeth A, Davies, Andrew and Collins, Graham P (2019) A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL. HEMATOLOGICAL ONCOLOGY, 37 (4). pp. 352-359.